The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).
 
Chigusa Morizane
Honoraria - Eisai; MSD K.K.; Novartis; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Abbvie; MSD K.K.; MSD K.K.; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - AstraZeneca (Inst); Eisai (Inst); J-Pharma (Inst); Merck (Inst); ONO PHARMACEUTICAL (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Nozomu Machida
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - MSD (Inst)
 
Yoshitaka Honma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai/Roche; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Teijin Pharma
Research Funding - Astellas Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Loxo (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Rakuten Medical (Inst); Taiho Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Lilly; Nihon Servier; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Syneos Health/Immunocore (Inst); Taiho Pharmaceutical (Inst)
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - AstraZeneca; Chugai Pharma; Pfizer
Research Funding - Amgen Astellas BioPharma (Inst); AstraZeneca (Inst)
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Shigeki Sekine
No Relationships to Disclose
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Naohiro Okano
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; J-Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - GlaxoSmithKline
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takuji Sato
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Nobumasa Mizuno
Honoraria - AstraZeneca; Fujifilm; MSD; Novartis; Yakult Honsha
Consulting or Advisory Role - AstraZeneca
Research Funding - ASLAN Pharmaceuticals (Inst); Eisai (Inst); Incyte (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Masato Ozaka
Honoraria - AstraZeneca; Bayer; EA Pharma; Eisai; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Tomoko Kataoka
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; DAINIPPON SUMITOMO PHARMA Co., Ltd.; EA Pharma; Eisai; Kaken Pharmaceutical; Nihon Pharma; Ono Pharmaceutical; Otsuka; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); DAINIPPON SUMITOMO PHARMA Co., Ltd. (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)
 
Masanori Terashima
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Lilly; Medtronic; Olympus; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst)
 
Junji Furuse
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD; Mylan; Nihon Servier; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Merck; MSD; Mundipharma; OncoTherapy Science; Ono Pharmaceutical; Takara Bio; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); J-Pharma (Inst); Merck (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)